The co-developer of a US-approved drug, Professor Andrew Wilks has formed Synthesis Bioventures to sniff out more winners.

December was a topsy turvy month for crypto, but growing stablecoin reserves could hint at a fresh rally as Trump's ...

The high-risk strategies employed by aggressive growth funds have paid off in a bumper year for members. Analysis by ...

Settling on a name for a mineral deposit isn’t quite as important as naming a child but it’s clear some are more creative ...

Aldoro led resources stock gains in December on strong niobium sampling results at its Kameelburg project in Namibia.

In this episode of the Unicorns podcast, Justin talks with Mark Schneider, Chief Nuclear Officer at UBH Group.

Tony Rovira was at the reins when Azure’s world-class Azure deposit was taken over by Hancock and SQM in a $1.7bn deal.

The Australian sharemarket surged in 2024, adding nearly $200bn to the value of the benchmark ASX 200 index, despite a ...

Donald Trump's re-election as US president adds to uncertainty for the year ahead, according to analysts who have given their ...

The ASX is on the up on Thursday, while Lendlease sells UK unit, Brainchip rallies again, the Aussie dollar drops and home ...

New data shows the 40 key ASX biotechs gained an average 50% in 2024 - but not all of them joined the winner's circle.

The ASX's big iron ore and coal stocks let down the local market in 2024, but there were a handful of bulk winners.